MX2009013629A - DERIVADO DE 17ß-CIANO-19-NOR-ANDROST-4-ENO, SU USO Y EL MEDICAMENTO QUE CONTIENE EL DERIVADO. - Google Patents
DERIVADO DE 17ß-CIANO-19-NOR-ANDROST-4-ENO, SU USO Y EL MEDICAMENTO QUE CONTIENE EL DERIVADO.Info
- Publication number
- MX2009013629A MX2009013629A MX2009013629A MX2009013629A MX2009013629A MX 2009013629 A MX2009013629 A MX 2009013629A MX 2009013629 A MX2009013629 A MX 2009013629A MX 2009013629 A MX2009013629 A MX 2009013629A MX 2009013629 A MX2009013629 A MX 2009013629A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- hydrogen
- derivative
- group
- androst
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 10
- 239000001257 hydrogen Substances 0.000 abstract 10
- 150000002431 hydrogen Chemical class 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 230000003152 gestagenic effect Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- -1 hydroxymethylene Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/008—3 membered carbocyclic rings in position 15/16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/007—3 membered carbocyclic rings in position 6-7
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Toxicology (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
(Ver fórmula (1)) Los derivados de 17ß-ciano-19-nor-androst-4-eno de la presente invención poseen efectividad gestágena. Poseen la fórmula química general 1, en la cual Z se selecciona del grupo que comprende O, dos átomos de hidrógeno, NOR y NNHSO2R, donde R es hidrógeno o C1-C4-alquilo, R4 es hidrógeno o halógeno, además o bien: R6a, R6b juntos forman metileno o 1,2-etandiilo o R6a es hidrógeno y R6b se selecciona del grupo que comprende hidrógeno, metilo y hidroximetileno, y R7 se selecciona del grupo que comprende hidrógeno, C1-C4-alquilo, C2-C3-alquenilo y ciclopropilo, o: R6a es hidrógeno y R6b y R7 juntos forman metileno o desaparecen por formación de un enlace doble entre C6 y C7., R9, R10 son hidrógeno o desaparecen por formación de un enlace doble entre C9 y C10, R15, R16 son hidrógeno o juntos forman metileno, R17 se selecciona del grupo que comprende hidrógeno, C1-C4-alquilo y allilo, donde al menos uno de los sustituyentes R4, R6a, R6b, R7, R15, R16 y R17 no es hidrógeno o R6b y R7 desaparecen por formación de un enlace doble entre C6 y C7, y sus solvatos, hidratos, estereoisómeros, diastereómeros, enantiómeros y sales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007027637A DE102007027637A1 (de) | 2007-06-12 | 2007-06-12 | 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| PCT/EP2008/004429 WO2008151746A2 (de) | 2007-06-12 | 2008-06-04 | 17β-CYANO-19-NOR-ANDROST-4-EN-DERIVAT, DESSEN VERWENDUNG UND DAS DERIVAT ENTHALTENDE ARZNEIMITTEL |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009013629A true MX2009013629A (es) | 2010-01-20 |
Family
ID=39986163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009013629A MX2009013629A (es) | 2007-06-12 | 2008-06-04 | DERIVADO DE 17ß-CIANO-19-NOR-ANDROST-4-ENO, SU USO Y EL MEDICAMENTO QUE CONTIENE EL DERIVADO. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8207150B2 (es) |
| EP (1) | EP2170925B1 (es) |
| JP (1) | JP2010529153A (es) |
| KR (1) | KR20100028554A (es) |
| CN (1) | CN101679478A (es) |
| AR (1) | AR066971A1 (es) |
| AU (1) | AU2008261278A1 (es) |
| BR (1) | BRPI0813937A2 (es) |
| CA (1) | CA2690959A1 (es) |
| DE (1) | DE102007027637A1 (es) |
| ES (1) | ES2397996T3 (es) |
| IL (1) | IL202359A0 (es) |
| MX (1) | MX2009013629A (es) |
| PA (1) | PA8784401A1 (es) |
| PE (1) | PE20090822A1 (es) |
| RU (1) | RU2010100331A (es) |
| TW (1) | TW200909444A (es) |
| UY (1) | UY31146A1 (es) |
| WO (1) | WO2008151746A2 (es) |
| ZA (1) | ZA201000187B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007027635A1 (de) * | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-19-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| DE102007027637A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| WO2010066355A1 (de) * | 2008-12-12 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | VERWENDUNG VON 17β- CYANO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG |
| WO2012059594A1 (en) | 2010-11-04 | 2012-05-10 | Bayer Pharma Aktiengesellschaft | Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity |
| CN104530165A (zh) * | 2014-12-10 | 2015-04-22 | 浙江仙琚制药股份有限公司 | 制备4,9-双烯物的方法 |
| CN105085596A (zh) * | 2015-08-18 | 2015-11-25 | 湖北竹溪人福药业有限责任公司 | 一种羧酸黄体酮的制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3043833A (en) * | 1961-07-14 | 1962-07-10 | Ormonoterapia Richter Spa | 17-cyanohydrin of 19-nor androstenedione and 3-derivatives thereof |
| DE1183500B (de) | 1962-10-12 | 1964-12-17 | Schering Ag | Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe |
| US3579509A (en) * | 1965-06-21 | 1971-05-18 | Smith Kline French Lab | Process and 6-beta-substituted ethyl intermediates for preparing 6,6-ethylene-3-keto-delta**4 steroids |
| GB1089945A (en) * | 1965-09-23 | 1967-11-08 | British Drug Houses Ltd | Steroidal-6-spirocyclopropyl-4-en-3-ones |
| CH538462A (de) * | 1970-10-07 | 1973-06-30 | Ciba Geigy Ag | Ein neues Verfahren zur Herstellung von 6a-Methyl-19-nor-pregnenen |
| US3705179A (en) | 1971-03-15 | 1972-12-05 | American Home Prod | Antiandrogenic steroids |
| FR2139708B1 (es) * | 1971-06-01 | 1974-08-23 | Roussel Uclaf | |
| BE795241A (fr) | 1972-02-11 | 1973-08-09 | Schering Ag | 15alpha, 16alpha-methylene-4-oestren-17beta-ols-methylenz-4-oestren-17beta-ols et leur procede de preparation |
| DE2456068A1 (de) | 1974-11-23 | 1976-08-12 | Schering Ag | Verfahren zur herstellung von oestren3,17-dion-derivaten |
| NL7701384A (nl) | 1977-02-10 | 1978-08-14 | Akzo Nv | Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks. |
| DE2922500A1 (de) | 1979-05-31 | 1980-12-04 | Schering Ag | 6 beta .7 beta |
| US4252800A (en) * | 1979-10-05 | 1981-02-24 | United States Of America | 7α-methylnorethindrone enanthate and its use in long term suppression of fertility in female mammals |
| US4512986A (en) * | 1983-07-26 | 1985-04-23 | Research Triangle Institute | Progrestationally active steroids |
| US4544554A (en) * | 1983-09-26 | 1985-10-01 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
| DE3402329A1 (de) | 1984-01-20 | 1985-08-01 | Schering AG, 1000 Berlin und 4709 Bergkamen | 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
| DD281394A5 (de) * | 1984-12-10 | 1990-08-08 | Jenapharm Veb | Verfahren zur herstellung von steroid-c-17 alpha-carbonitrilen |
| DD281393A5 (de) * | 1984-12-10 | 1990-08-08 | Jenapharm Veb | Verfahren zur herstellung von steroid-c-17 beta-carbonitrilen |
| DE4344462C2 (de) * | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
| EP0785211A1 (en) * | 1996-01-22 | 1997-07-23 | Laboratoire Theramex | New substituted 19-nor-pregnane derivatives |
| DE19651000A1 (de) | 1996-12-01 | 1998-06-04 | Schering Ag | Oxyiminopregnancarbolactone |
| DE102004063864A1 (de) | 2004-12-30 | 2006-07-13 | Schering Ag | 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate |
| DE102007027637A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
-
2007
- 2007-06-12 DE DE102007027637A patent/DE102007027637A1/de not_active Withdrawn
-
2008
- 2008-06-04 AU AU2008261278A patent/AU2008261278A1/en not_active Abandoned
- 2008-06-04 RU RU2010100331/04A patent/RU2010100331A/ru not_active Application Discontinuation
- 2008-06-04 WO PCT/EP2008/004429 patent/WO2008151746A2/de active Application Filing
- 2008-06-04 KR KR1020097025930A patent/KR20100028554A/ko not_active Application Discontinuation
- 2008-06-04 BR BRPI0813937-7A2A patent/BRPI0813937A2/pt not_active Application Discontinuation
- 2008-06-04 ES ES08758990T patent/ES2397996T3/es active Active
- 2008-06-04 MX MX2009013629A patent/MX2009013629A/es not_active Application Discontinuation
- 2008-06-04 CN CN200880020020A patent/CN101679478A/zh active Pending
- 2008-06-04 EP EP08758990A patent/EP2170925B1/de not_active Not-in-force
- 2008-06-04 JP JP2010511526A patent/JP2010529153A/ja active Pending
- 2008-06-04 CA CA2690959A patent/CA2690959A1/en not_active Abandoned
- 2008-06-11 UY UY31146A patent/UY31146A1/es not_active Application Discontinuation
- 2008-06-11 TW TW097121802A patent/TW200909444A/zh unknown
- 2008-06-11 PA PA20088784401A patent/PA8784401A1/es unknown
- 2008-06-11 PE PE2008000994A patent/PE20090822A1/es not_active Application Discontinuation
- 2008-06-11 US US12/137,111 patent/US8207150B2/en not_active Expired - Fee Related
- 2008-06-12 AR ARP080102499A patent/AR066971A1/es unknown
-
2009
- 2009-11-26 IL IL202359A patent/IL202359A0/en unknown
-
2010
- 2010-01-11 ZA ZA2010/00187A patent/ZA201000187B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2397996T3 (es) | 2013-03-13 |
| DE102007027637A1 (de) | 2008-12-18 |
| WO2008151746A3 (de) | 2009-03-12 |
| IL202359A0 (en) | 2010-06-30 |
| CN101679478A (zh) | 2010-03-24 |
| CA2690959A1 (en) | 2008-12-18 |
| BRPI0813937A2 (pt) | 2014-12-30 |
| US8207150B2 (en) | 2012-06-26 |
| AU2008261278A1 (en) | 2008-12-18 |
| KR20100028554A (ko) | 2010-03-12 |
| RU2010100331A (ru) | 2011-07-20 |
| EP2170925A2 (de) | 2010-04-07 |
| AR066971A1 (es) | 2009-09-23 |
| JP2010529153A (ja) | 2010-08-26 |
| PE20090822A1 (es) | 2009-07-25 |
| TW200909444A (en) | 2009-03-01 |
| UY31146A1 (es) | 2009-01-30 |
| EP2170925B1 (de) | 2012-10-24 |
| PA8784401A1 (es) | 2009-01-23 |
| US20090048217A1 (en) | 2009-02-19 |
| ZA201000187B (en) | 2011-03-30 |
| WO2008151746A2 (de) | 2008-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009013626A (es) | DERIVADO DE 17ß-CIANO-18A-HOMO-19-NOR-ANDROST-4-ENO, SU USO Y MEDICAMENTO QUE LO CONTIENE. | |
| EP2597088A4 (en) | P2X4 Receptor Antagonists | |
| MX2009013629A (es) | DERIVADO DE 17ß-CIANO-19-NOR-ANDROST-4-ENO, SU USO Y EL MEDICAMENTO QUE CONTIENE EL DERIVADO. | |
| TW200833675A (en) | Nicotinamide derivatives | |
| TW200642683A (en) | Heterocyclic compound | |
| MX2021008356A (es) | Inhibidores de jak2 y alk2 y metodos para su uso. | |
| WO2010026436A3 (en) | 1,3, 4, 6, 7, 11b-hexahydro-benzo[alpha]quinolizines for the treatment of hyperkinetic movement and related disorders | |
| MX2009005604A (es) | Inhibidores espiro cetona de acetil-coa carboxilasa. | |
| TW200639158A (en) | New compounds with therapeutic effect | |
| MX2013003019A (es) | Compuestos de azabenzotiazol, composiciones y metodos de uso. | |
| DE602006011752D1 (de) | Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate | |
| TW200612920A (en) | Novel imidazolidine derivatives | |
| MX2009006689A (es) | Inhibidores viia de los factores macrociclicos utiles como anticoagulantes. | |
| JO2673B1 (en) | Diosmetin compounds, method of preparation and pharmaceutical compositions | |
| EA200900631A1 (ru) | Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена) | |
| MX2013007938A (es) | Compuesto biciclico novedoso o sal del mismo. | |
| MY183326A (en) | New dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | |
| MXPA05011176A (es) | Derivados de carboxamida como agentes antidiabeticos. | |
| WO2005003087A3 (en) | Oxazole derivatives as antibacterial agents | |
| MX2012004835A (es) | Derivados de espirolactama y usos de los mismos. | |
| MY161992A (en) | Novel tetrahydroisoquinoline derivative | |
| MX2009013631A (es) | DERIVADO DE 17ß-CIANO-19-ANDROST-4-ENO, SU USO Y MEDICAMENTOS QUE COMPRENDEN AL DERIVADO. | |
| WO2003093247A3 (en) | Antibacterial agents | |
| WO2009019721A3 (en) | Quercetin derivatives as anti-cancer agents | |
| WO2009130469A8 (en) | Dna-pk inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |